Newcells Biotech Secures Funding for Innovative Drug Development
Newcells Biotech, a promising venture situated in Newcastle, UK, is making significant strides in the field of drug development through innovative laboratory models. Recently, the company secured £1.2 million in funding, a move that reflects the confidence investors have in its potential. The funding round saw participation from established backers such as Mercia Ventures, Northstar Ventures, and North East Finance. These financial resources will play a pivotal role in Newcells' strategy to expand its customer base while forging new partnerships with companies that offer complementary products, thereby enriching its overall service offering to clients.
Founded in 2015 by the esteemed Dr.
Mike Nicholds and the renowned Professor Lyle Armstrong, Newcells Biotech emerged as a spin-out from the University of Newcastle. This dynamic company is focused on revolutionizing the way drugs are tested and developed by providing advanced 3D models that closely imitate human tissues. These innovative models serve a critical function in assessing the viability of drugs under development and offer essential data that guide pharmaceutical companies in making informed decisions regarding which drugs should progress to human trials. This capability is especially important in today's fast-paced medical landscape, where efficiency and accuracy are paramount.
One of the significant advantages of utilizing Newcells’ 3D models lies in their ability to expedite the drug development process while also reducing dependence on traditional animal testing methods. In many cases, these advanced models have shown superior capabilities in predicting how a drug will function within the human body, thus allowing for more informed projections and decisions. Currently, Newcells offers specialized models for various organs, including the retina, kidney, and lung. Additionally, the company provides comprehensive testing services on behalf of its customers, further demonstrating its commitment to supporting the pharmaceutical industry in bringing safe and effective drugs to market more swiftly and cost-effectively.
They've invested in Newcells
Get to know these Healthtech investors
Click here for a full list of 6,481+ startup investors in the UK